Jim Simons Collegium Pharmaceutical, Inc Transaction History

Renaissance Technologies LLC

$63.1 Billion
Q3 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Collegium Pharmaceutical, Inc stock. As of the latest transaction made, Renaissance Technologies LLC holds 1,656,069 shares of COLL stock, worth $48.3 Million. This represents 0.1% of its overall portfolio holdings.

Number of Shares

1,656,069

Previous 1,531,498 8.13%

Holding current value

$48.3 Million

Previous $49.3 Million 29.76%

% of portfolio

0.1%

Previous 0.09%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$31.4 - $39.07 $3.91 Million - $4.87 Million	124,571 Added 8.13%	1,656,069 $64 Million
Q2 2024 Aug 09, 2024	BUY	$31.36 - $39.99 $3.55 Million - $4.53 Million	113,300 Added 7.99%	1,531,498 $49.3 Million
Q1 2024 May 13, 2024	BUY	$31.23 - $40.91 $1.05 Million - $1.37 Million	33,600 Added 2.43%	1,418,198 $55.1 Million
Q4 2023 Feb 13, 2024	BUY	$21.16 - $30.8 $4.49 Million - $6.53 Million	212,000 Added 18.08%	1,384,598 $42.6 Million
Q3 2023 Nov 14, 2023	SELL	$21.23 - $24.28 $2.17 Million - $2.49 Million	-102,400 Reduced 8.03%	1,172,598 $26.2 Million
Q2 2023 Aug 11, 2023	BUY	$21.06 - $24.0 $1.4 Million - $1.6 Million	66,500 Added 5.5%	1,274,998 $27.4 Million
Q1 2023 May 12, 2023	BUY	$23.0 - $29.88 $1.25 Million - $1.62 Million	54,179 Added 4.69%	1,208,498 $29 Million
Q4 2022 Feb 13, 2023	SELL	$16.14 - $23.55 $1.4 Million - $2.04 Million	-86,499 Reduced 6.97%	1,154,319 $26.8 Million
Q3 2022 Nov 14, 2022	SELL	$15.46 - $20.1 $2.41 Million - $3.14 Million	-156,000 Reduced 11.17%	1,240,818 $19.9 Million
Q2 2022 Aug 12, 2022	BUY	$14.22 - $20.88 $1.8 Million - $2.65 Million	126,700 Added 9.98%	1,396,818 $24.8 Million
Q1 2022 May 13, 2022	BUY	$17.2 - $22.5 $237,360 - $310,500	13,800 Added 1.1%	1,270,118 $25.9 Million
Q4 2021 Feb 11, 2022	SELL	$17.5 - $21.35 $851,882 - $1.04 Million	-48,679 Reduced 3.73%	1,256,318 $23.5 Million
Q3 2021 Nov 12, 2021	BUY	$17.75 - $25.39 $984,752 - $1.41 Million	55,479 Added 4.44%	1,304,997 $25.8 Million
Q2 2021 Aug 13, 2021	SELL	$21.74 - $25.28 $352,188 - $409,536	-16,200 Reduced 1.28%	1,249,518 $29.5 Million
Q1 2021 May 13, 2021	SELL	$19.25 - $26.1 $2.25 Million - $3.05 Million	-117,000 Reduced 8.46%	1,265,718 $30 Million
Q4 2020 Feb 10, 2021	SELL	$17.83 - $22.29 $850,490 - $1.06 Million	-47,700 Reduced 3.33%	1,382,718 $27.7 Million
Q3 2020 Nov 13, 2020	SELL	$15.78 - $20.82 $3.11 Million - $4.1 Million	-196,900 Reduced 12.1%	1,430,418 $29.8 Million
Q2 2020 Aug 13, 2020	BUY	$15.49 - $23.51 $630,443 - $956,857	40,700 Added 2.57%	1,627,318 $28.5 Million
Q1 2020 May 14, 2020	BUY	$13.89 - $25.45 $4.64 Million - $8.51 Million	334,290 Added 26.69%	1,586,618 $25.9 Million
Q4 2019 Feb 13, 2020	BUY	$10.7 - $22.24 $5.4 Million - $11.2 Million	505,128 Added 67.6%	1,252,328 $25.8 Million
Q3 2019 Nov 13, 2019	BUY	$10.16 - $13.28 $5.11 Million - $6.68 Million	503,100 Added 206.1%	747,200 $8.58 Million
Q2 2019 Aug 12, 2019	BUY	$10.62 - $16.59 $2.59 Million - $4.05 Million	244,100 New	244,100 $3.21 Million

Others Institutions Holding COLL

# of Institutions

255

Shares Held

36.9M

Call Options Held

100K

Put Options Held

21.1K

View Full List

About COLLEGIUM PHARMACEUTICAL, INC

Ticker COLL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 34,126,200
Market Cap $995M
Description
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ...

More about COLL

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account